Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer{star, open}

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 4 SPEC. ISS., 2006, Pages 344-348

  Joudi, Fadi N ^a   Smith, Brian J ^b   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Bladder neoplasms; Clinical trial; Drug therapy; Treatment outcome

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; RECOMBINANT ALPHA2B INTERFERON;

AGED; BLADDER CANCER; CANCER RECURRENCE; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; SUPERFICIAL CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 33745513016     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.11.026     Document Type: Review

References (9)

1. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Malkowicz S.B. Management of superficial bladder cancer. In: Walsh P.C., Retik A.B., Vaughan E.D., et al. (Eds). Campbell's urology. 8th ed (2002), Saunders, Philadelphia (PA) 2785-2802
3. Brown D.H., Wagner T.T., and Bahnson R.R. Interferons and bladder cancer. Urol Clin North Am 27 (2000) 171-178
4. Luo Y., Chen X., Downs T., et al. IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guerin immunotherapy. J Immunol 162 (1999) 2399-2405
5. Punnen S.P., Chin J.L., and Jewett M.A. Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer. Results with intravesical BCG and Interferon combination therapy. Can J Urol 10 (2003) 1790-1795
6. Lam J.S., Benson M.C., O'Donnell M.A., et al. Bacillus Calmette-Guerin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity. Urol Oncol 21 (2003) 354-360
7. O'Donnell M.A., Lilli K., and Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 172 (2004) 888-893
8. Esuvaranathan K. Five-year data of a randomized controlled trial of standard dose BCG versus low dose BCG and interferon-alpha in patients with superficial bladder cancer. J Urol 171 Suppl (2004) 73 [Abstract 276]
9. Rodriguez-Alonso A., Pita-Fernandez S., Gonzalez-Carrero J., et al. Multivariate analysis of survival, recurrence, progression and development of metastasis in T1 and T2a transitional cell bladder carcinoma. Cancer 94 (2002) 1677-1684